Scientists test new drug duo in fight against tough nasal cancers
NCT ID NCT00336063
Summary
This early-stage trial is testing the safety and best dose of a two-drug combination (vorinostat and azacitidine) for patients with advanced nasal and throat cancers that have returned or spread. The study aims to see if these drugs, which work differently to stop cancer cell growth, are safe to give together and might be more effective. It involves a small group of up to 18 adults whose cancer has progressed despite prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NASOPHARYNGEAL KERATINIZING SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese University of Hong Kong-Prince of Wales Hospital
Shatin, Hong Kong
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
National Cancer Center Hospital
Tokyo, 104 0045, Japan
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
National University Hospital Singapore
Singapore, 119074, Singapore
Conditions
Explore the condition pages connected to this study.